期刊文献+

蓝贻贝抗凝肽的合成及活性初步研究

Preliminary study on synthesis and activity of blue mussel anticoagulant peptide
原文传递
导出
摘要 目的采用多肽固相合成法合成蓝贻贝抗凝肽MEAP(Blue mussel Mytilus edulis anticoagulant peptide),初步研究其抗凝活性。方法以2-CTC树脂为载体,Fmoc保护氨基酸为原料,按照蓝贻贝抗凝肽的序列从C端向N端逐步偶联氨基酸,裂解后得到粗肽,经半制备液相纯化后测定精肽的凝血酶时间(TT)、活化的部分凝血活酶时间(APTT)、凝血酶原时间(PT)。结果合成的蓝贻贝抗凝肽粗品的纯度为65.5%,经半制备纯化后的精肽纯度为95.5%;抗凝活性实验显示APTT、TT具有显著的延时作用(P<0.01)。结论固相合成的蓝贻贝抗凝肽具有抗凝活性。 Objective To prepare blue mussel Mytilus edulis anticoagulant peptide (MEAP) by using sol- id phase peptide synthesis method and to preliminarily study its anticoagulant activity. Methods MEAP was successfully synthesized from its C terminal to N terminal according to its peptide sequence by u- sing 2-CTC resin as the solid supporter and Fmoc amino acids as raw materials. The crude peptide was cleaved from the resin and purified by RP-HPLC. The thrombin time (TT), activation of blood coagu- lation time (APTT) and prothrombin time (PT) of purified MEAP were determined. Results The puri- ties of synthetic crude and purified MEAP were 65.5 % and 95.5%, respectively. Anticoagulant activi- ty experiments showed that both APTT and TT of synthetic MEAP had significant delayed effect (P〈0.01). Conclusion MEAP obtained by using solid phase peptide synthesis method had anticoagulant ac- tivity.
出处 《中国海洋药物》 CAS CSCD 2015年第5期59-62,共4页 Chinese Journal of Marine Drugs
基金 河北省海外高层次人才"百人计划"项目(E201200002)资助
关键词 蓝贻贝 抗凝肽 固相合成 抗凝活性 blue mussel anticoagulant peptide solid-phase synthesis anticoagulant activity
  • 相关文献

参考文献7

  • 1康伟.海洋生物活性物质发展研究[J].亚太传统医药,2014,10(3):47-48. 被引量:5
  • 2孙继鹏,易瑞灶,吴皓,洪碧红,陈俊德.海洋药物的研发现状及发展思路[J].海洋开发与管理,2013,30(3):7-13. 被引量:16
  • 3Kaiser L-Colescott R L,Bossinger C D,et al.Color test for detection of free terminal amino groups in the solid}hase synthesis ofpeptides[J].Analytical Biochem,1970,34 (2) :595.
  • 4Merrifield R B.Solid phase synthesis[J].Science,1986,232:341-347.
  • 5Jung W K,Kim S K.Isolation and characterization of an anticoagulant oligopeptide from bluemussel,Mytilus edulis[J].Food Chemistry,2009,117:687-692.
  • 6代涛,尹志峰,赵红玲,高杨,李云红,李松涛,王良友.布舍瑞林的合成[J].中国新药杂志,2014,23(15):1806-1810. 被引量:7
  • 7Kaiser E,-Colescott R L,Bossinger C D,et al.Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides[J].Analytical Biochem,1970,34 (2) :595.

二级参考文献34

  • 1林浩,王德心.哌嗪二酮衍生物的合成研究进展[J].药学学报,2003,38(5):395-400. 被引量:11
  • 2方翼,陈騉,梁蓓蓓,裴斐,柴栋,王睿.单次静滴D-聚甘酯注射液在中国健康人体的安全性[J].中国临床药理学杂志,2004,20(4):283-286. 被引量:7
  • 3田玲,路学智.瑞林类人工合成肽类药物的研究进展[J].中国新药杂志,2006,15(20):1723-1726. 被引量:15
  • 4武国海,周彩红,王明伟.前列腺癌治疗药物的研究新进展[J].中国新药杂志,2007,16(17):1330-1336. 被引量:4
  • 5GLASER K B, MAYER A M S. A renaissance in marine pharmacology: from preclinical curiosity to clinical reality [ J ]. Biochemical Pharmacology, 2009,78:440--448.
  • 6SOARES D G, ESCARGUEIL A E, POINDES- SOUS V,et al. Replication and homologous recom- bination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743[J]. Proc. Natl. Acad. Sci, 2007, 104:13062 -- 13067.
  • 7CARTER N J, KEAM S J. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer [J]. Drugs, 2007, 67:2257-- 2276.
  • 8YOUNES A, BARTLETT N L. Brentuximab redo tin(SGN--35) for relapsed CD30-Positive lympho mas[J]. The New England Journal of Medicine, 2010,363 :1812-- 1821.
  • 9KRICK A, KEHRAUS S, GERHAUSER C, et al. Potential cancer chemopreventive in vitro activi- ties of monomeric xanthone derivatives from the marine algicolous fungus Monodictys putredinis [J]. J. Nat Prod, 2007, 70(3) :353--360.
  • 10KOHAYASHI H, SUNAGA R, FURIHATA K, et al. Isolatation and structures of an antifungal an- tibioties, Fusarielin A, and related compounds pro- duced by a Fusarium sp. [J]. J. Antibiotics, 1995, 48(1) :42-46.

共引文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部